SEC Comment Letter 0000000000-23-003433 to Aceragen, Inc. (CIK 0000861838)
Aceragen, Inc. (CIK 0000861838)
Date: April 5, 2023 · CIK: 0000861838 · Accession: 0000000000-23-003433
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo April 5, 2023 Christopher J. Hubbert Partner Kohrman Jackson & Krantz LLP 1375 East Ninth Street One Cleveland Center, 29th Floor Cleveland, OH 44114 Re:Aceragen, Inc. Schedule 13D filed by Atul Chopra Filed March 28, 2023 File No. 005-50211 Dear Christopher J. Hubbert: We have reviewed the above-captioned filing, and have the following comment. Please respond to this letter by amending the filing or by providing the requested information. If a belief exists that our comment does not apply to your facts and circumstances or that an amendment is inappropriate, please advise us why in a response letter. After reviewing any amendment to the filing and any information provided in response to this comment, we may have additional comments. Schedule 13D filed by Atul Chopra on March 28,2023 General 1.We note the date of the event reported as requiring the filing of the Schedule 13D was September 28, 2022. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within 10 days after the acquisition of more than five percent of a class of equity securities specified in Rule 13d-1(i). Based on the September 28, 2022 event date, the Schedule 13D submitted on March 28, 2023 was not timely filed. Please advise us why the Schedule 13D was not filed within the required 10 days after the acquisition. We remind you that the filing person is responsible for the accuracy and adequacy of the disclosure in the above-captioned Schedule 13D, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameChristopher J. Hubbert Comapany NameKohrman Jackson & Krantz LLP April 5, 2023 Page 2 FirstName LastName Christopher J. Hubbert Kohrman Jackson & Krantz LLP April 5, 2023 Page 2 Please direct any questions to Michael Killoy at (202) 551-7576 or Nicholas Panos at (202) 551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
United States securities and exchange commission logo
April 5, 2023
Christopher J. Hubbert
Partner
Kohrman Jackson & Krantz LLP
1375 East Ninth Street
One Cleveland Center, 29th Floor
Cleveland, OH 44114
Re:Aceragen, Inc.
Schedule 13D filed by Atul Chopra
Filed March 28, 2023
File No. 005-50211
Dear Christopher J. Hubbert:
We have reviewed the above-captioned filing, and have the following comment.
Please respond to this letter by amending the filing or by providing the requested
information. If a belief exists that our comment does not apply to your facts and circumstances or
that an amendment is inappropriate, please advise us why in a response letter.
After reviewing any amendment to the filing and any information provided in response to
this comment, we may have additional comments.
Schedule 13D filed by Atul Chopra on March 28,2023
General
1.We note the date of the event reported as requiring the filing of the Schedule 13D was
September 28, 2022. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule
13D within 10 days after the acquisition of more than five percent of a class of equity
securities specified in Rule 13d-1(i). Based on the September 28, 2022 event date, the
Schedule 13D submitted on March 28, 2023 was not timely filed. Please advise us why
the Schedule 13D was not filed within the required 10 days after the acquisition.
We remind you that the filing person is responsible for the accuracy and adequacy of
the disclosure in the above-captioned Schedule 13D, notwithstanding any review, comments,
action or absence of action by the staff.
FirstName LastNameChristopher J. Hubbert
Comapany NameKohrman Jackson & Krantz LLP
April 5, 2023 Page 2
FirstName LastName
Christopher J. Hubbert
Kohrman Jackson & Krantz LLP
April 5, 2023
Page 2
Please direct any questions to Michael Killoy at (202) 551-7576 or Nicholas Panos at
(202) 551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions